{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-105015","form_type":"8-K","ticker":"ACLX","cik":"0001786205","company_name":"Arcellx, Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.988594+00:00","generated_at":"2026-05-17T18:03:34.272574+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Arcellx reports 97% ORR from anito-cel Phase 2; FDA clears ACLX-004 IND; Q2 net loss $52.8M","bullets":["Phase 2 iMMagine-1: 97% ORR, 68% CR/sCR at 12.6 months; no delayed neurotoxicity events observed.","FDA cleared IND for ACLX-004 (CD33/CD123) ARC-SparX platform for AML.","Q2 2025 net loss $52.8M vs $27.2M in Q2 2024; rev $7.6M (down from $27.4M).","Cash $537.6M expected to fund operations into 2028.","Plan to launch anito-cel at >160 US treatment centers within first year."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-105015","json":"https://secwatch.observer/filing/0000950170-25-105015.json","markdown":"https://secwatch.observer/filing/0000950170-25-105015.md","text":"https://secwatch.observer/filing/0000950170-25-105015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1786205/000095017025105015/0000950170-25-105015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1786205/000095017025105015/aclx-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T18:03:34.272574+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}